Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Total Liabilities: 2023-2025

Historic Total Liabilities for Artiva Biotherapeutics (ARTV) over the last 3 years, with Sep 2025 value amounting to $19.6 million.

  • Artiva Biotherapeutics' Total Liabilities fell 20.17% to $19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.6 million, marking a year-over-year decrease of 20.17%. This contributed to the annual value of $22.9 million for FY2024, which is 54.77% down from last year.
  • Per Artiva Biotherapeutics' latest filing, its Total Liabilities stood at $19.6 million for Q3 2025, which was down 3.50% from $20.4 million recorded in Q2 2025.
  • Over the past 5 years, Artiva Biotherapeutics' Total Liabilities peaked at $174.7 million during Q1 2024, and registered a low of $19.6 million during Q3 2025.
  • For the 3-year period, Artiva Biotherapeutics' Total Liabilities averaged around $70.2 million, with its median value being $37.6 million (2024).
  • Data for Artiva Biotherapeutics' Total Liabilities shows a maximum YoY slumped of 87.13% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Artiva Biotherapeutics' Total Liabilities stood at $50.7 million in 2023, then plummeted by 54.77% to $22.9 million in 2024, then fell by 20.17% to $19.6 million in 2025.
  • Its Total Liabilities was $19.6 million in Q3 2025, compared to $20.4 million in Q2 2025 and $22.5 million in Q1 2025.